REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
06/15/2026
Back to search
Official data from USPTO
NANOBIOTIX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
31
Latest update
06/16/2026
Trademark type
Combined
Nice classes
5, 10, 42, 44
Filing date
06/30/2020
Registration date
06/15/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/15/2021
Last transaction
06/16/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
33
Owner location
FR
Examiner
ADEYIGA, ADETAYO JANET
Law office
L90
Current location
TMEG LAW OFFICE 109
Mark description
The sign consists of the denomination "NANOBIOTIX" in black capital letters, with the stretched letter "B", which makes it looks extended.
Holders and representatives
Holders
Nanobiotix
Representatives
James R Menker Holley & Menker, PA
Technical classification
Nice Classes
Class 5Class 10Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical productspreparations for medical use particularly for tumor diagnosis and treatment; pharmaceutical productspreparations for medical useespecially for the diagnosis and treatment of tumors using radiotherapy; radioactive productssubstances for medical useespecially for the diagnosis and treatment of tumors using radiotherapy; health productspharmaceutical productsfor the treatment of tumors; radiological contrast substances for medical use; chemical reagents for medical use; chemical preparations for medical or pharmaceutical usefor the treatment of tumors; diagnostic products for medical usemedicines for the treatment of tumors; drugs for medical usepharmaceutical products for use in the treatment of cancer; medicines for human medicinepharmaceutical products for the treatment of tumors; chemico-pharmaceutical products for use in treating oncological diseases and disorders; pharmaceutical products for use in treating oncological diseases and disorders
Class 10
Surgical and medical apparatus and instrumentsnamely radiotherapy apparatus especially for the diagnosis and treatment of tumors using radiotherapy; radiotherapy apparatus; testing apparatus for medical usefor testing tumor characteristics; diagnostic apparatus for medical usefor testing tumor characteristics; radiological apparatus for medical use; apparatus and installations for the production of X-Rays for medical use
Class 42
Scientific and technological servicesresearch and design services particularly in the field of nanomedicine which is nanotechnology applied to medicine; biological research; research in bacteriology; scientific researchevaluationsestimates and research in scientific and technological fields provided by engineersresearchers; design and development of new products for third parties; technical project studiestechnical research in the field of nanomedicine; industrial analysis of manufacturing of nanomedicines and research services in the field of nanomedicine; chemical analysis; chemical research; chemistry serviceschemistry consultation; surveying
Class 44
Healthcare especially in the field of nanomedicine; medical services especially in the field of nanomedicine; hospital services; medical assistance; physiotherapy
Publications
History of USPTO decisions and trademark events.
31 publications found
CORN
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
06/03/2022
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
04/23/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
10/30/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/01/2021
FIMP
FINAL DISPOSITION PROCESSED
10/01/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/15/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
06/15/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/30/2021
PUBO
PUBLISHED FOR OPPOSITION
03/30/2021
GPNX
NOTIFICATION PROCESSED BY IB
03/28/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/10/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
03/10/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/10/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/24/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
02/24/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/24/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
02/24/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/24/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/15/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/15/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/15/2021
RFNT
REFUSAL PROCESSED BY IB
11/02/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
10/13/2020
RFRR
REFUSAL PROCESSED BY MPU
10/13/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
10/09/2020
CNRT
NON-FINAL ACTION WRITTEN
10/08/2020
DOCK
ASSIGNED TO EXAMINER
10/06/2020
MAFR
APPLICATION FILING RECEIPT MAILED
09/08/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/04/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/03/2020
Continuous trademark protection
Get notified about every new filing that threatens NANOBIOTIX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.